title: A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
abstract: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a potentially curative treatment for multiple myeloma (MM); however, because of high treatment-related mortality (TRM), its role is not well defined. Patients with newly diagnosed, relapsed, or primary refractory myeloma were enrolled in a randomized phase II trial of 2 reduced-intensity conditioning regimens: fludarabine 120 mg/m(2) + melphalan 100 mg/m(2) (FM100) versus fludarabine 120 mg/m(2) + melphalan 140 mg/m(2) (FM140) before allo-HCT from related or unrelated donors. Fifty patients underwent allo-HCT using FM100 (n = 23) or FM140 (n = 27) conditioning between April 2002 and 2011. There were no significant differences between FM100 and FM140 in time to neutrophil engraftment (P = .21), acute grade II to IV graft-versus-host disease (GVHD) (P = 1.0), chronic GVHD (P = .24), response rate (P = 1.0), TRM (13% versus 15%, P = 1.0), median progression-free survival (PFS), 11.7 versus 8.4 months, P = .12, and median overall survival (OS), 35.1 versus 19.7 months, P = .38. Cumulative incidence of disease progression in FM100 and FM140 was 43% and 70%, respectively (P = .08). Recurrent disease was the most common cause of death for both FM100 (26%) and FM140 (44%), P = .24. On multivariate analysis, disease status at allo-HCT, complete response or very good partial response (VGPR) was significantly associated with longer PFS (15.6 versus 9.6 months in patients with <VGPR, P = .05). OS was similar across all variables. We conclude that FM100 and FM140 may result in similar patient outcomes after allo-HCT for MM.
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas. Electronic address: qbashir@mdanderson.org.
authors.forename: Qaiser
authors.initials: Q
authors.lastname: Bashir
authors.forename: Hassan
authors.initials: H
authors.lastname: Khan
authors.forename: Peter F
authors.initials: PF
authors.lastname: Thall
authors.forename: Ping
authors.initials: P
authors.lastname: Liu
authors.forename: Nina
authors.initials: N
authors.lastname: Shah
authors.forename: Partow
authors.initials: P
authors.lastname: Kebriaei
authors.forename: Simrit
authors.initials: S
authors.lastname: Parmar
authors.forename: Betul
authors.initials: B
authors.lastname: Oran
authors.forename: Stefan
authors.initials: S
authors.lastname: Ciurea
authors.forename: Yago
authors.initials: Y
authors.lastname: Nieto
authors.forename: Roy
authors.initials: R
authors.lastname: Jones
authors.forename: Chitra M
authors.initials: CM
authors.lastname: Hosing
authors.forename: Uday R
authors.initials: UR
authors.lastname: Popat
authors.forename: Yvonne T
authors.initials: YT
authors.lastname: Dinh
authors.forename: Gabriela
authors.initials: G
authors.lastname: Rondon
authors.forename: Robert Z
authors.initials: RZ
authors.lastname: Orlowski
authors.forename: Jatin J
authors.initials: JJ
authors.lastname: Shah
authors.forename: Marcos
authors.initials: M
authors.lastname: De Lima
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Shpall
authors.forename: Richard
authors.initials: R
authors.lastname: Champlin
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
authors.forename: Muzaffar H
authors.initials: MH
authors.lastname: Qazilbash
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000601:surgery* / Q000628:therapy; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D014740:Vidarabine; C024352:fludarabine; D008558:Melphalan
keywords: Allogeneic transplantation; Fludarabine; Melphalan; Myeloma; Reduced-intensity conditioning